Tests two cholesterol targets in people who had a small-vessel stroke
Compares stricter and standard LDL cholesterol lowering in adults with small-vessel stroke.
Key facts
- Who runs it
- Seoul National University Hospital
- Where
- Ansan, Anyang, Busan, Changwon, Cheongju-si, Chuncheon, Daegu, Daejeon, Goyang, Guri-si, Gwangju, Gwangmyeong, Hwaseong, Iksan, Incheon, Jeju City, Seongnam, Seoul, and Yŏngin, South KoreaSee the 46 sites
- Trial code
- NCT06649240
- KCT0009043
- Registry title
- Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
- Status
- Recruiting
- People taking part
- 4,016 people, planned
- Started
- 4 Oct 2024
- Expected to end
- Sept 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Statins and/or Ezetimibe
- PCSK9 inhibitor
- Record updated
- 11 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a stroke caused by a small blocked blood vessel in the last 180 days. It compares two LDL cholesterol targets.
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- A symptomatic ischemic stroke from a small vessel blockage deep in the brain or in the brainstem, seen on MRI or CT. The stroke happened within 180 days before joining.
- Earlier treatment
- People whose LDL cholesterol was below 70 mg/dL (1.8 mmol/L) without any cholesterol-lowering medicine cannot join.
Main reasons for not taking part
- Narrowing of a large artery in or outside the brain of 50% or more
- Earlier stroke caused by atherosclerosis, or a transient ischemic attack
- Known coronary artery disease, peripheral artery disease or aortic atherosclerotic disease
- Diabetes with a long duration, several risk factors or organ damage, as listed in the record
- Cannot take statins, or pregnant, breastfeeding or planning pregnancy
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age 19 years or older
- Patients with objectively confirmed small vessel occlusive infarctions in the subcortical or brainstem regions, identified through neuroimaging (MRI or CT)
- Patients with a history of symptomatic ischemic stroke caused by the lesion described in 2), occurring within 180 days prior to enrollment
- Patients or guardians who agree to the study protocol and sign with informed consent
Who cannot take part
- History of atherosclerotic ischemic stroke or transient ischemic attack
- Documented coronary artery disease
- Documented peripheral artery disease or aortic atherosclerotic disease
- Diabetes with one or more of the following: duration ≥10 years; ≥2 major risk factors (men ≥45 years, women ≥55 years; family history of premature atherosclerotic cardiovascular disease; hypertension; current smoking; or HDL cholesterol <40 mg/dL); or known evidence of target organ damage (albuminuria, estimated glomerular filtration rate <60 mL/min per 1.73 m², retinopathy, neuropathy, or left ventricular hypertrophy)
- Baseline LDL cholesterol <70 mg/dL in the absence of lipid-lowering therapy (statins, ezetimibe, PCSK9 inhibitors, etc.)
- Patients contraindicated for statin use (e.g., active liver disease, serum transaminase levels elevated more than three times the normal limit, muscle disorders, hypersensitivity to statins, or taking medications contraindicated for use with statins)
- Extracranial or intracranial large artery stenosis ≥50%
- Women who are pregnant, breastfeeding, or intending to become pregnant during the study period
- Deemed unsuitable for participation in the study for more than four years, as per the investigators' discretion
Where in South Korea
- Korea University Ansan HospitalAnsan, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Hallym University Sacred Heart HospitalAnyang, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Pusan National University HospitalBusan, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Gyeongsang National University Changwon hospitalChangwon, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Samsung Changwon HospitalChangwon, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Chungbuk National University HospitalCheongju-si, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Hallym University Chuncheon Sacred Heart HospitalChuncheon, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Kangwon National University HospitalChuncheon, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Daegu Catholic University Medical CenterDaegu, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Keimyung University - Dongsan Medical CenterDaegu, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Kyungpook National University Chilgok HospitalDaegu, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Kyungpook National University HospitalDaegu, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Chungnam National University HospitalDaejeon, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Daejeon Eulji Medical CenterDaejeon, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Ilsan Paik HospitalGoyang, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- National Health Insurance Service Ilsan HospitalGoyang, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Dongguk University Ilsan HospitalGoyang, South KoreaContact: Wookjin Yang, MD, PhDNo longer taking part
- Hanyang University Guri HospitalGuri-si, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Chonnam National University HospitalGwangju, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Chosun University HospitalGwangju, South KoreaContact: Wookjin Yang, MD, PhDNo longer taking part
- Chung-Ang University Gwangmyeong HospitalGwangmyeong, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Dongtan Sacred Heart HospitalHwaseong, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Wonkwang University HospitalIksan, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Gachon University Gil Medical CenterIncheon, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Inha University HospitalIncheon, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- International St. Mary's HospitalIncheon, South KoreaContact: Wookjin Yang, MD, PhDNo longer taking part
- Jeju National University HospitalJeju City, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Seoul National University Bundang HospitalSeongnam, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Asan Medical CenterSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Chung ang University HospitalSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Ewha Womans University Mokdong HospitalSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Ewha Womans University Seoul HospitalSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Gangnam Severance HospitalSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Hallym University Kangdong Sacred Heart HospitalSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Hanyang University Seoul HospitalSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Konkuk University Medical CenterSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Korea University Anam HospitalSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Kyung Hee University Medical CenterSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- National Medical CenterSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Nowon Eulji Medical CenterSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Samsung Medical CenterSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Seoul Metropolitan Government Seoul National University Boramae Medical CenterSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Seoul National University HospitalSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Severance hospitalSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Yeouido St. Mary's HospitalSeoul, South KoreaContact: Wookjin Yang, MD, PhDTaking people
- Yongin Severance HospitalYŏngin, South KoreaContact: Wookjin Yang, MD, PhDTaking people
About the trial
What the trial wants to find out
Lipid-lowering therapy constitutes a cornerstone of secondary prevention in ischemic stroke; however, current stroke guidelines remain deficient in providing optimal target low-density lipoprotein (LDL)-cholesterol levels tailored to the stroke subtypes. Most clinical trials on LDL-cholesterol management have not differentiated between stroke subtypes or have primarily focused on large artery atherosclerosis (LAA) stroke, leaving a gap in evidence for managing LDL-cholesterol in other stroke subtypes, e.g., small vessel occlusion (SVO) stroke. While hypertension is the leading risk factor for SVO strokes, the link between elevated LDL-cholesterol and SVO stroke is also recognized. Establishing optimal LDL-cholesterol targets for SVO stroke would significantly enhance secondary prevention strategies and improve patient outcome. Thus, the investigators aim to compare intensive versus standard lipid-lowering in patients with SVO stroke. SVO70 is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial. Adult participants with objectively confirmed SVO stroke within 180 days of randomization will be included. Exclusion criteria include those with predefined LDL-cholesterol targets for other conditions, baseline LDL-cholesterol <70 mg/dL in the absence of lipid-lowering therapy, statin contraindications, or women who are pregnant, breastfeeding, or planning pregnancy during the study period. Eligible participants will be randomized 1:1 to target LDL-cholesterol <70 mg/dL (intensive group) or 90-110 mg/dL (standard group). The trial plans to enroll 4,016 participants, with the primary outcome being major adverse cardiovascular events-cardiovascular death, stroke, and acute coronary syndrome-during a follow-up period of at least 4 years. This study would provide valuable information for determining the optimal LDL-cholesterol target for patients with SVO stroke.
The 2 groups in the trial
- Intensive groupTreatment being tested
Target LDL-cholesterol \<70 mg/dL
Treatment: Statins and/or Ezetimibe and PCSK9 inhibitor
- Standard groupExisting treatment, for comparison
Target LDL-cholesterol 90-110 mg/dL
Treatment: Statins and/or Ezetimibe and PCSK9 inhibitor
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)
- Plain-language title
- Tests two cholesterol targets in people who had a small-vessel strokeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- SVO70 (Optimal Target Low-Density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke): Rationale and Study Design.Journal of the American Heart Association, 2026
- Record updated
- 11 September 2026